HCQ is an anti-malarial agent, which is also commonly used to treat multiple autoinflammatory diseases, including those to which the NLRP3 inflammasome is known to contribute: rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome (Nirk et al., 2020). Here, NLRP3 is linked to Sjogren syndrome.